Biotech stocks offer potential high returns from developing drugs and therapies. Investing in biotech involves risks, such as clinical failures and regulatory hurdles. Diversified investment options ...

But what if a lesser-known candidate, from a smaller biotech company, ultimately gives both Novo Nordisk and Lilly a run for their money? It's not just hype that has led pharmaceutical stocks like ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...

Biotech stocks have rallied strongly into 2026, building on the late-2025 momentum from positive clinical data, cheaper valuation, easy money policy and favorable macro conditions. Biotech-based ...

Learning how to trade biotech stocks offers some of the most explosive profit opportunities in the entire market—but also some of its most punishing risks. Biotech stocks can double or triple ...

The words “sure-fire” and biotechnology stocks rarely go together. This is a sector of the stock market that carries higher-than-average risk. The success of these companies depends on clinical trial ...

The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the ...

Edmund Ingham of Haggerston BioHealth shares his 6-tab due diligence process on Seeking Alpha Premium, covering CRISPR, cash ...

This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer ...

The long winter for biotech stocks is over. Shares have climbed to levels not seen since late 2021, buoyed by eye-popping takeover valuations, trailblazing innovation in battling obesity and cancer, ...

Biotech investors have rarely united so strongly against a Food and Drug Administration official as they did against Vinay Prasad, who led the FDA's vaccines and related biological products division a ...